Activation of Melanocortin Receptors MC₁ and MC₅ Attenuates Retinal Damage in Experimental Diabetic Retinopathy

Table 1

Mean glycemia levels (mg/dl) in nondiabetic and diabetic mice treated with melanocortin receptor agonists/antagonists.

Mean glycemia levels (mg/dl ± SEM)
Weeks	Nondiabetic mice	Diabetic mice	Diabetic mice + BMS	Diabetic mice + MTII	Diabetic mice + PG-901	Diabetic mice + AGRP	Diabetic mice + SHU	Diabetic mice + PG20N
8	80 ± 8	330 ± 8	315 ± 16	345 ± 12	315 ± 17	324 ± 7	355 ± 19	335 ± 14
12	90 ± 10	335 ± 20	310 ± 15	325 ± 14	327 ± 13	354 ± 18	312 ± 10	325 ± 16
16	80 ± 12	320 ± 14	305 ± 12	355 ± 10	346 ± 24	342 ± 21	333 ± 16	340 ± 9

Intravitreal injections (5 µl) every 4 weeks from the onset of diabetes with BMS = BMS-470539 (MC₁ agonist, 33 µmol); MTII (MC₃-MC₄ agonist, 9.3 nmol); PG-901 (MC₅ agonist, 7.32 nM); AGRP (MC₁ antagonist, 1 µg/mouse); SHU = SHU9119 (MC₃-MC₄ antagonist, 9 nmol); PG20N (MC₅ antagonist, 130 nM).